Treatment efficacy of ledipasvir/sofosbuvir for 8 weeks in non-cirrhotic chronic hepatitis C genotype 4 patients

BACKGROUND/AIMS: Ledipasvir/sofosbuvir (LDV/SOF) combination is administered for 12 to 24 weeks to treat hepatitis C virus (HCV); guidelines recommend 8 weeks treatment duration for HCV genotype (GT) 1 infection based on the patient's baseline characteristics. Data on treating HCV GT4 with LDV/...

Descripción completa

Detalles Bibliográficos
Autores principales: Babatin, Mohammed A., AlGhamdi, Abdullah S., Assiri, Abdullah M., AlBiladi, Haziz, AlOthmani, Hammad S., Mogharbel, Mohammed H., Mahallawi, Wedad, Asselah, Tarik, Sanai, Faisal M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6373216/
https://www.ncbi.nlm.nih.gov/pubmed/30117490
http://dx.doi.org/10.4103/sjg.SJG_189_18

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6373216/
https://www.ncbi.nlm.nih.gov/pubmed/30117490
http://dx.doi.org/10.4103/sjg.SJG_189_18

Ejemplares similares